✦ LIBER ✦

High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study

✍ Scribed by Meloni, G; Capria, S; Trasarti, S; Ferrazza, G; Micozzi, A; Petrucci, M T; Simone, F; Trisolini, S M; Mandelli, F

Book ID: 110012833
Publisher: Nature Publishing Group
Year: 2000
Tongue: English
Weight: 57 KB
Volume: 26
Category: Article
ISSN: 0007-1188
DOI: 10.1038/sj.bmt.1702668

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose idarubicin, cyclophosphamide a

High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study

✍ R. Fenk; P. Schneider; M. Kropff; A. N. Huenerlituerkoglu; U. Steidl; C. Aul; B. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB

High-dose idarubicin and busulphan as co

High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia

✍ Felicetto Ferrara; Salvatore Palmieri; Mariacarla De Simone; Marco Sagristani; A 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB

Busulfan, cyclophosphamide, and etoposid

Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma

✍ Christopher R. Cogle; Jan S. Moreb; Helen L. Leather; Katarzyna J. Finiewicz; Sh 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 2 views

## Abstract Autologous stem cell transplantation (ASCT) has enabled the use of high‐dose alkylating agents either as a single agent or in combination with other cytotoxic agents and/or total body irradiation (TBI) for the treatment of multiple myeloma. Despite improved complete remission rates, rel

Amifostine reduces mucosal damage after

Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma

✍ Thieblemont, C; Dumontet, C; Saad, H; Roch, N; Bouafia, F; Arnaud, P; Hequet, O; 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 111 KB

High-dose melphalan versus busulfan, cyc

High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma

✍ Don M. Benson Jr.; Patrick J. Elder; Thomas S. Lin; William Blum; Sam Penza; Bel 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 192 KB

A Phase II study of 153Sm-EDTMP and high

A Phase II study of 153Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma

✍ Angela Dispenzieri; Gregory A. Wiseman; Martha Q. Lacy; Suzanne R. Hayman; Shaji 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views